Intellectual Property
The development work at Cyxone and the research performed by collaborating scientists continues to generate new patent opportunities for the company, and we regularly assess those opportunities.
In order to increase the commercial potential for Rabeximod and its attractiveness to potential partners, we are taking measures to expand its market exclusivity period. A number of additional patent applications have recently been filed, and we will continue exploring more options to further expand our IP platform.
Rabeximod Patents
| Patent name | Geographies | Expiration date |
|---|---|---|
| Alkyl substituted indoloquinoxalines | USA, UK, France, Spain, Germany, Sweden, India, China, Mexico, Japan | 2025 EU/row 2028 USA |
| New use of Rabeximod (for use in any form for treatment of a pathogenic infection and acute respiratory syndromes), PCT/EP2021/065693 | TBD | 2041 + PE |
| Rabeximod in treatment in RA (for treating any stage of RA), PCT/EP2021/065697 | TBD | 2041 + PE |
| New oral formulation (formulation of Rabeximod in crystalline form), PCT/EP2021/065705 | TBD | 2041 + PE |
| Large scale process (process for manufacturing Rabeximod), PCT/EP2021/065694 | TBD | 2041 + PE |
T20K Patents
| Patent name | Geographies | Expiration date |
|---|---|---|
| Cyclotides as immunosuppressive agents* | USA, Europe, Canada, Australia | 2032 EU/row/USA + PE |
| Cyclotides in combination with kappa opioid receptor ligands for MS therapy* | TBD | 2041 + PE |
* Patent is co-owned by the Medical University of Vienna and the University of Freiburg, with Cyxone AB holding an exclusive fully paid-up license